Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THEO-260 in Advanced Ovarian Cancer
NCT07211659Phase 1Recruiting
- Sponsor
- Theolytics
- Start
- Feb 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of THEO-260 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Theolytics. Primary endpoints: Safety and tolerability of THEO-260 at Day 28 and Recommended Phase 2 Dose at 18 months. Started Feb 2026; status: recruiting.
02
Drugs
THEO-260
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07211659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07211659.